This is in agreement with a previous study showing that an alternative Endo180 mAb vc-MMAE conjugate reduced viability of Endo180-positive sarcoma cell lines in vitro and had efficacy against an Endo180-positive human myeloid leukemia xenograft (19). This evidence concerns the gene MRC2 and myeloid leukemia.